文献速递类风湿关节炎

类风湿关节炎的终身风险、预期寿命与医疗支出:2003-2016年台湾全国队列研究

Lifetime Risks, Life Expectancy, and Health Care Expenditures for Rheumatoid Arthritis: A Nationwide Cohort Followed Up From 2003 to 2016.
PubMed 文献 · Arthritis Rheumatol · 2021-03-02

该研究基于台湾全民健康保险1999-2016年理赔数据,识别2003-2016年29,352例新发类风湿关节炎(RA)病例,估计16-84岁人群累积发病率呈下降趋势,RA患者诊断后平均预期寿命26.3年,平均终身医疗支出72,953美元,平均损失预期寿命4.97年,女性RA患者预期寿命较同龄男性长1-2年但损失预期寿命更高,终身支出也更高。

要点

  • 2003-2016年台湾新发RA共29,352例,16-84岁累积发病率男女均呈下降趋势。
  • RA患者诊断后平均预期寿命26.3年,平均损失预期寿命4.97年,平均终身医疗支出72,953美元。
  • 女性RA患者较同龄男性RA患者预期寿命长1-2年,但损失预期寿命更高且终身支出更高。

核心结论

  • 生物制剂可用后,RA患者活得更长且终身医疗支出更高,应监测并评估成本效果。

研究设计与样本

  • 利用台湾全民健康保险1999-2016年理赔数据,并与重大伤病登记库验证建立研究队列,识别2003-2016年新发RA病例。
  • 采用滚动算法估计RA生存函数并外推至终身,为每例RA患者模拟性别、年龄和日历年匹配的参照人群以估计预期寿命。
  • 以平均月医疗支出乘以相应生存率并终身求和计算终身医疗支出。

主要发现

  • 2003-2016年共识别29,352例新发RA病例,16-84岁累积发病率男女均呈下降趋势。
  • RA诊断后平均预期寿命26.3年,平均终身医疗支出72,953美元,平均损失预期寿命4.97年。
  • 女性RA患者较同龄男性RA患者预期寿命长1-2年,导致前者终身支出更高。
  • 台湾女性预期寿命较男性高6-7年,故女性RA患者损失预期寿命高于男性RA患者。
  • 男女RA患者年度医疗支出相似。

临床怎么用

  • 临床中应关注RA患者预期寿命损失及终身医疗支出,尤其女性RA患者损失预期寿命更高。
  • 生物制剂时代RA患者生存改善但终身支出增加,需在临床决策中考虑成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study was undertaken to estimate the cumulative incidence rate of rheumatoid arthritis (RA) in the Taiwanese population ages 16-84 years, and life expectancy, loss of life expectancy, and lifetime health care expenditures for incident RA in Taiwan after 2003, when biologics began to be prescribed. METHODS: We obtained all claims data for the period 1999 to 2016 from the National Health Insurance program of Taiwan, and validated the data against the Catastrophic Illness Registry to establish the study cohort. We estimated the survival function for RA and extrapolated to lifetime using a rolling-over algorithm. For every RA case, we simulated sex-, age-, and calendar year-matched referents from vital statistics and estimated their life expectancy. The difference between the life expectancy of the referent and the life expectancy of the RA patient was the loss of life expectancy for the RA patient. Average monthly health care expenditures were multiplied by the corresponding survival rates and summed up throughout the lifetime to calculate the lifetime health care expenditures. RESULTS: A total of 29,352 new RA cases were identified during 2003-2016. There was a decreasing trend in cumulative incidence rate in those ages 16-84 for both sexes. Mean life expectancy after diagnosis of RA was 26.3 years, and mean lifetime cost was $72,953. RA patients had a mean loss of life expectancy of 4.97 years. Women with RA survived 1-2 years longer than men with RA of the same age, which resulted in higher lifetime expenditures for the former. Since the life expectancy for women in Taiwan was 6-7 years higher than that for men, the loss of life expectancy for women with RA was higher than that for men with RA. Annual health care expenditures were similar for both sexes. CONCLUSION: Our findings indicate that since biologics became available, RA patients have lived longer and had higher lifetime expenditures, which should be monitored and evaluated for cost-effectiveness.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Chiu YM, Lu YP, Lan JL, et al. Lifetime Risks, Life Expectancy, and Health Care Expenditures for Rheumatoid Arthritis: A Nationwide Cohort Followed Up From 2003 to 2016. Arthritis Rheumatol. 2021. PMID: 33295139. doi:10.1002/art.41597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。